NUVB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.14% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	3.62M
Vidutinė apimtis	1.40M
Rinkos kapitalizacija	721.74M
EPS	$-0.0675 ( Q1 \| 2024-05-14 )
Kita pelno data	( $-0.0600 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.12 (Sector) 49.64 (Industry) 46.06
ATR14	$0.00900 (0.31%)

ADCT 12.46%

AMAM 0.07%

ANRO 0.56%

ANTX -3.59%

BHVN -1.08%

BWV -6.97%

DNA 8.12%

DNA-WT -0.35%

DYN -0.37%

GLS 0.00%

KDMN 0.00%

MYOV -0.04%

NUVB -3.95%

NUVB-WT -0.18%

NVO -1.21%

PRME -3.56%

RCUS 0.40%

SQZ 61.11%

TOVX -2.80%

ZYME 1.19%

Insider Trading

Date	Person	Action	Amount	type
2024-06-25	Cui Xiangmin	Buy	277 895	Class A Common Stock
2024-06-24	Cui Xiangmin	Buy	336 874	Class A Common Stock
2024-06-21	Cui Xiangmin	Buy	75 411	Class A Common Stock
2024-06-20	Cui Xiangmin	Buy	87 715	Class A Common Stock
2024-06-11	Blickenstaff Kim D	Buy	172 189	Class A Common Stock

INSIDER POWER
89.31
Last 97 transactions
Buy: 45 073 738 \| Sell: 9 223 361

Koreliacija (AI algo v.1.1b): Undervalued: 0.14% $2.92 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.56 (weak negative)

Trumpas: -0.92 (very strong negative)

Signal:(24.008) Possible Trading Opportunity Present (swing)

Panacea Acquisition Corp. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CNM	0.95
NEE-PR	0.945
EDF	0.941
SN	0.94
ECO	0.936
WSM	0.934
MTAL-WT	0.933
TXO	0.93
GM	0.929
OBDC	0.929

10 Labiausiai neigiamai susiję koreliacijos
STVN	-0.925
SHPW	-0.92
SVV	-0.911
MPU	-0.91
CRT	-0.905
LITB	-0.905
ZVIA	-0.901
BNKD	-0.898
ELIQ	-0.892
SIJ	-0.889

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Panacea Acquisition Corp. Koreliacija - Valiuta/Žaliavos

-0.31
( neutral )

0.49
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.00
( neutral )

-0.26
( neutral )

Panacea Acquisition Corp. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-222 000 (0.00 %)
EPS:	$-0.350

FY	2023
Pajamos:	$0
Bruto pelnas:	$-222 000 (0.00 %)
EPS:	$-0.350

FY	2022
Pajamos:	$0
Bruto pelnas:	$-484 000 (0.00 %)
EPS:	$-0.410

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.440

Financial Reports:

No articles found.

Panacea Acquisition Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Panacea Acquisition Corp.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.